GymnemageninCAS# 22467-07-8 |
- Protoaescigenin
Catalog No.:BCC8240
CAS No.:20853-07-0
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 22467-07-8 | SDF | Download SDF |
| PubChem ID | 10051937 | Appearance | White powder |
| Formula | C30H50O6 | M.Wt | 506.71 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in methanol; sparingly soluble in chloroform; insoluble in water | ||
| Chemical Name | (3R,4R,4aR,5S,6aR,6aS,6bR,8aR,9R,10S,12aR,14bS)-4a,9-bis(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-3,4,5,10-tetrol | ||
| SMILES | CC1(CC2C3=CCC4C5(CCC(C(C5CCC4(C3(CC(C2(C(C1O)O)CO)O)C)C)(C)CO)O)C)C | ||
| Standard InChIKey | VKJLHZZPVLQJKG-ABHKXHSUSA-N | ||
| Standard InChI | InChI=1S/C30H50O6/c1-25(2)13-18-17-7-8-20-26(3)11-10-21(33)27(4,15-31)19(26)9-12-28(20,5)29(17,6)14-22(34)30(18,16-32)24(36)23(25)35/h7,18-24,31-36H,8-16H2,1-6H3/t18-,19+,20+,21-,22-,23-,24-,26-,27-,28+,29+,30-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Gymnemagenin, one of the key constituents of G. sylvestre against 15 proteins having key role in carbohydrate metabolism, it can be considered further for development into a potent anti-diabetic drug. 2. Gymnemagenin has antihyperglycemic activity. 3. Gymnemagenin is a potent and selective antagonist for the β isoform of LXR. |
| Targets | Liver X Receptor |
Gymnemagenin Dilution Calculator
Gymnemagenin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9735 mL | 9.8676 mL | 19.7352 mL | 39.4703 mL | 49.3379 mL |
| 5 mM | 0.3947 mL | 1.9735 mL | 3.947 mL | 7.8941 mL | 9.8676 mL |
| 10 mM | 0.1974 mL | 0.9868 mL | 1.9735 mL | 3.947 mL | 4.9338 mL |
| 50 mM | 0.0395 mL | 0.1974 mL | 0.3947 mL | 0.7894 mL | 0.9868 mL |
| 100 mM | 0.0197 mL | 0.0987 mL | 0.1974 mL | 0.3947 mL | 0.4934 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- MLCK inhibitor peptide 18
Catalog No.:BCC5828
CAS No.:224579-74-2
- Benfotiamine
Catalog No.:BCC1415
CAS No.:22457-89-2
- Retapamulin
Catalog No.:BCC4837
CAS No.:224452-66-8
- Ginsenoside Rg1
Catalog No.:BCN1066
CAS No.:22427-39-0
- Bayogenin methyl ester
Catalog No.:BCN3722
CAS No.:22425-81-6
- 2,2'-Anhydro-5-methyluridine
Catalog No.:BCC8486
CAS No.:22423-26-3
- Incensole
Catalog No.:BCN3831
CAS No.:22419-74-5
- Siramesine hydrochloride
Catalog No.:BCC5134
CAS No.:224177-60-0
- 3-Epiturraeanthin
Catalog No.:BCN5063
CAS No.:22415-24-3
- Cyclobuxine D
Catalog No.:BCC9221
CAS No.:2241-90-9
- Aristola-1(10),8-dien-2-one
Catalog No.:BCN7608
CAS No.:22391-34-0
- 3,8-Di-O-methylellagic acid
Catalog No.:BCN5062
CAS No.:2239-88-5
- 18-Norabieta-8,11,13-trien-4-ol
Catalog No.:BCN5064
CAS No.:22478-65-5
- Vardenafil HCl Trihydrate
Catalog No.:BCC2277
CAS No.:224785-90-4
- Erigeside I
Catalog No.:BCN7172
CAS No.:224824-74-2
- N-(1-hydroxy-2-(hydroxymethyl)-4-(4-octylphenyl)butan-2-yl)acetamide
Catalog No.:BCN1483
CAS No.:2249289-10-9
- IDRA 21
Catalog No.:BCC6974
CAS No.:22503-72-6
- Falcarindiol
Catalog No.:BCN5065
CAS No.:225110-25-8
- Cathepsin Inhibitor 1
Catalog No.:BCC4896
CAS No.:225120-65-0
- 8-Hydroxy-9,10-diisobutyryloxythymol
Catalog No.:BCN7786
CAS No.:22518-08-7
- CTU Guanamine
Catalog No.:BCC8921
CAS No.:22535-90-6
- Ocotillone
Catalog No.:BCN5066
CAS No.:22549-21-9
- Robustine
Catalog No.:BCN6653
CAS No.:2255-50-7
- Isocryptotanshinone
Catalog No.:BCN2499
CAS No.:22550-15-8
In-silico analysis of gymnemagenin from Gymnema sylvestre (Retz.) R.Br. with targets related to diabetes.[Pubmed:26711684]
J Theor Biol. 2016 Feb 21;391:95-101.
Diabetes is a metabolic disorder characterized by higher than normal glucose in the blood. Most oral hypoglycemic drugs available in market produce adverse side effects which have resulted in continued search for new therapeutic agents with little or no side effects. Herbal drugs are considered relatively safer alternatives and Gymnema sylvestre is one of the most well established natural remedy for diabetes and is traded worldwide under several brands. In the present study an attempt has been made to use in silico techniques to understand and predict the drug likeliness of Gymnemagenin, one of the key constituents of G. sylvestre against 15 proteins having key role in carbohydrate metabolism. Gymnemagenin was found to dock well with crystallographic structures of 7 of the 15 selected targets and was found even better than the two known clinically used antidiabetic compounds, repaglinide and sitagliptin taken in the study for comparison. Gymnemagenin therefore can be considered further for development into a potent anti-diabetic drug.
Hypoglycemic activity of Gymnema sylvestre extracts on oxidative stress and antioxidant status in diabetic rats.[Pubmed:22360666]
J Agric Food Chem. 2012 Mar 14;60(10):2517-24.
Diabetes mellitus, which is associated with oxidative damage, has a significant impact on health, quality of life, and life expectancy. An ethanol extract of Gymnema sylvestre leaf was examined in vitro and in vivo to investigate the role of antioxidants in diabetic rats. The extract exhibited strong antioxidant activity in the assays, including TBA (56%), SOD-like (92%), and ABTS (54%). Blood glucose levels in the diabetic rats fed G. sylvestre extract decreased to normal levels. The presence of the antihyperglycemic compounds Gymnemagenin and gymnemic acids in G. sylvestre extract was detected by LC/MS analysis. Lipid peroxidation levels were decreased by 31.7% in serum, 9.9% in liver, and 9.1% in kidney in the diabetic rats fed the extract. Feeding G. sylvestre extract to the diabetic rats decreased the activity of glutathione peroxidase in cytosolic liver and glutamate pyruvate transaminase in serum to normal levels.
Molecular decodification of gymnemic acids from Gymnema sylvestre. Discovery of a new class of liver X receptor antagonists.[Pubmed:25668616]
Steroids. 2015 Apr;96:121-31.
The individual chemical components of commercial extract of Gymnema sylvestre, a medicinal plant used in the traditional systems of the Indian medicine for its antidiabetic and hypolipidemic properties, were isolated and evaluated for their capability to act as modulators of nuclear and membrane receptors involved in glucose and lipid homeostasis. The study disclosed for the first time that individual gymnemic acids are potent and selective antagonists for the beta isoform of LXR. Indeed the above activity was shared by the most abundant aglycone Gymnemagenin (10) whereas gymnestrogenin (11) was endowed with a dual LXRalpha/beta antagonistic profile. Deep pharmacological investigation demonstrated that gymnestrogenin, reducing the expression of SREBP1c and ABCA1 in vitro, is able to decrease lipid accumulation in HepG2 cells. The results of this study substantiate the use of G. sylvestre extract in LXR mediated dislypidemic diseases.
